Release primary care capacity with home testing

Reduce chronic disease management backlogs and improve kidney health outcomes with digital screening

Match Funding Now Available in partnership with NHSx, the Accelerated Access Collaborative and the National Institute for Health Research, are offering substantial match-funded opportunities to shift kidney health testing out of clinic settings across the UK.

This nationally significant programme, announced by Health and Social Care Secretary Matt Hancock, aims to release primary care capacity by allowing people at increased risk of chronic kidney disease (CKD) to complete their annual urine test at home.  Staff in participating GP practices will no longer have to process urine samples and vulnerable patients at increased risk of contracting COVID don’t have to visit the surgery to take their test.

We are seeking immediate expressions of interest from PCNs, CCGs, STPs, and other providers which specialise in this area of healthcare. 

Key Benefits

How It Works
Reach patients who are not engaging with traditional models of kidney testing by allowing them to self-test when it’s most convenient, without leaving home.
UK kit icon

We send ACR test kits directly to eligible patients' homes with their prior consent

Smartphone Urinalysis including app, cup, and dipstick

Patients self-test using our test kit and smartphone app, which guides them easily

Results transmitted to EMR

Results are analysed and uploaded to SystmOne or EMIS workflows in real time

Modality GP Partnership Testimonial Video
What Patients Say

found the test 'easy' or 'very
easy' to use

96% icon

preferred testing at home
vs. testing at the clinic

would recommend this service
to a friend

Clinical-Grade Testing from Home

The CKD early detection service increases adherence to annual urinary albumin to creatinine ratio (ACR) testing, which is known to be beneficial in the early detection and prevention of CKD, is recommended by NICE, and monitored by the National Diabetes Audit.

The test is built around the existing ACR point of care dipstick. It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).

Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).

The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.

Call for Expressions of Interest

Subsidised (50%) deployments of the service are available to innovative, forward-thinking partners interested in empowering their patients and improving care through an evidence-based, time-saving, and patient-focused digital technology.

Please submit your expression of interest by 5 pm on 11th June. Once submitted, we will be in touch to discuss the next steps towards releasing these benefits for your patient population at scale.

Please contact [email protected] with any questions.

By providing this information, you consent to receive relevant content from (You may opt out at any point.) For more information, visit our Privacy Policy.

By providing this information, you consent to receive relevant content from For more information, visit our Privacy Policy.
  1. Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024